Human HVEM/TNFRSF14 enzyme-linked immunoassay kit
| Specification | 96 Test |
|---|---|
| Sensitivity | 1.68 pg/ml (50 μl)；1.86 pg/ml (10 μl) |
| Standard Curve Range | 13.72~10000 pg/ml |
| Standard Curve Gradient | 7 Points/3 Folds |
| Number of Incubations | 2 |
| Sample Volume | 50 μl/10 μl |
| Type | Fully Ready-to-Use |
| Operation Duration | 120min |
| pg/ml | O.D. | Average | Corrected | |
|---|---|---|---|---|
| 0.00 | 0.0193 | 0.0194 | 0.0194 | |
| 13.72 | 0.0363 | 0.0381 | 0.0372 | 0.0179 |
| 41.15 | 0.0732 | 0.0746 | 0.0739 | 0.0546 |
| 123.46 | 0.1891 | 0.1851 | 0.1871 | 0.1678 |
| 370.37 | 0.5121 | 0.5123 | 0.5122 | 0.4929 |
| 1111.11 | 1.3600 | 1.3770 | 1.3685 | 1.3492 |
| 3333.33 | 2.8210 | 2.8440 | 2.8325 | 2.8132 |
| 10000.00 | 4.1600 | 4.0765 | 4.1183 | 4.0989 |
Precision
| Intra-assay Precision | Inter-assay Precision | |||||
| Sample Number | S1 | S2 | S3 | S1 | S2 | S3 |
| 22 | 22 | 22 | 6 | 6 | 6 | |
| Average(pg/ml) | 222.9 | 1101.3 | 3269.9 | 214.7 | 1006.4 | 3038.2 |
| Standard Deviation | 11.7 | 44.4 | 201.4 | 8.3 | 50.4 | 164.1 |
| Coefficient of Variation(%) | 5.2 | 4.0 | 3.6 | 3.9 | 5.0 | 5.4 |
Intra-assay Precision (Precision within an assay) Three samples of known concentration were tested twenty times on one plate to assess intra-assay precision.
Inter-assay Precision (Precision between assays) Three samples of known concentration were tested six times on one plate to assess intra-assay precision.
Spike Recovery
The spike recovery was evaluated by spiking 3 levels of human HVEM/TNFRSF14 into health human serum sample. The un-spiked serum was used as blank in this experiment.
The recovery ranged from 82% to 117% with an overall mean recovery of102%.
Sample Values
| Sample Matrix | Sample Evaluated | Range (pg/ml) | Detectable (%) | Mean of Detectable (pg/ml) |
|---|---|---|---|---|
| Serum | 30 | 6823.75-12125.82 | 100 | 8948.2 |
Serum/Plasma – Thirty samples from apparently healthy volunteers were evaluated for the presence of IL-12/IL-23 p40 in this assay. No medical histories were available for the donors.
Product Data Sheet
Background: HVEM/TNFRSF14
Herpesvirus entry mediator (HVEM), also referred to as TR2 (TNF receptor-like molecule) and ATAR (another TRAF-associated receptor), is a type I membrane protein belonging to the TNF/NGF receptor superfamily. In the TNF superfamily nomenclature, HVEM is referred to as TNFRSF14. Human HVEM cDNA encodes a 283 amino acid (aa) protein with a probable 36 aa signal peptide, a 166 aa extracellular domain, a 23 aa transmembrane region and a 58 aa cytoplasmic region. The extracellular domain of HVEM contains several cysteine-rich repeats characteristic of TNF receptor superfamily members. The short cytoplasmic region lacks a death domain present in some TNF receptor family members, but contains a TRAF (TNF receptor-associated factor) interaction domain. HVEM expression has been detected in peripheral blood T cells, B cells, monocytes and in various tissues enriched in lymphoid cells. The extracellular domain of HVEM has been shown to interact directly with the herpes simplex virus envelope glycoprotein D. Two TNF superfamily ligands, including the secreted TNF‑ beta (lymphotoxin alpha ) and the membrane protein LIGHT (lymphotoxins, exhibits inducible expression, and competes with HSV glycoprotein D for HVEM, a receptor expressed by T lymphocytes), have been shown to be the cellular ligands for HVEM. Besides HVEM, LIGHT can also interact with LT beta R, the receptor for lymphotoxin alpha beta heterotrimer.
